Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
United Laboratories International Holdings (FRA:UNJ) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
United Laboratories International Holdings's Enterprise Value for the quarter that ended in Dec. 2025 was €1,756 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. United Laboratories International Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €314 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Laboratories International Holdings EV-to-EBIT Related Terms
United Laboratories International Holdings EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Laboratories International Holdings EV-to-EBIT Chart
United Laboratories International Holdings Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, United Laboratories International Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Laboratories International Holdings EV-to-EBIT vs Drug Manufacturers Industry
United Laboratories International Holdings's current Enterprise Value is €1,134 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. United Laboratories International Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €314 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Laboratories International Holdings (FRA:UNJ) has a EV-to-EBIT of 3.62 as of Aug. 31, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on United Laboratories International Holdings and its competitors. This is 49% below median its historical median of 7.16. Over the past decade, United Laboratories International Holdings' EV-to-EBIT has ranged from 2.47 to 142.03. According to the industry distribution chart, United Laboratories International Holdings ranks #46 out of 685 companies in the Drug Manufacturers industry, placing it in the top 6.7%.
Is United Laboratories International Holdings' EV-to-EBIT too high?
United Laboratories International Holdings' current EV-to-EBIT of 3.62 is 49% below median its 10-year median of 7.16. Over the past 10 years, this metric has ranged from a low of 2.47 to a high of 142.03. The Drug Manufacturers industry median EV-to-EBIT is 16.22. United Laboratories International Holdings' value of 3.62 is 77.7% below this industry median. Based on the distribution chart, United Laboratories International Holdings ranks #46 out of 685 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, United Laboratories International Holdings has a GF Score™ of 67/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does United Laboratories International Holdings' EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, United Laboratories International Holdings ranks #46 out of 685 companies for EV-to-EBIT. This places United Laboratories International Holdings in the top 7% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 16.22. United Laboratories International Holdings' value of 3.62 is 77.7% below this benchmark. Historically, United Laboratories International Holdings' own EV-to-EBIT has ranged from 2.47 to 142.03 over the past decade. While the company's 10-year median is 7.16 vs. the industry median of 16.22, United Laboratories International Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 16.22, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. United Laboratories International Holdings's current EV-to-EBIT of 3.62 is 77.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on United Laboratories International Holdings and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 16.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. United Laboratories International Holdings's current EV-to-EBIT is 3.62, which is 49% below median its own 10-year median of 7.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Laboratories International Holdings stock overvalued right now?
Based on GuruFocus' analysis, United Laboratories International Holdings (FRA:UNJ) is currently considered Fairly Valued. The stock's GF Value™ is €0.94, compared to a current price of €0.92 — trading 2.7% below its estimated fair value. The current EV-to-EBIT is 3.62, which is 49% below median its 10-year median of 7.16 and 77.7% below the Drug Manufacturers industry median of 16.22. United Laboratories International Holdings' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For United Laboratories International Holdings (FRA:UNJ), the current EV-to-EBIT is 3.62 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is United Laboratories International Holdings (FRA:UNJ) Overvalued in 2026?
Based on GuruFocus' analysis, United Laboratories International Holdings stock appears to be undervalued.
The current stock price of €0.92 is trading 2.7% below its estimated GF Value™ of €0.94.
GuruFocus considers United Laboratories International Holdings to be Fairly Valued.
Key valuation signals for FRA:UNJ:
EV-to-EBIT: 3.62 (49% below median its 10-year median of 7.16)
GF Value™: €0.94 vs. price of €0.92 (2.7% below fair value)
Industry Position: 77.7% below the Drug Manufacturers median (#46 of 685)
No single metric tells the full story. See the FRA:UNJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
United Laboratories International Holdings Ltd is mainly engaged in the research and development, production and sales of pharmaceuticals. The company operates in three segments: Intermediate products, Bulk medicine, and Finished products. The company's Finished products segment includes antibiotic products, insulin series products, and other medicines. The vast majority of the company's revenue is derived from its Finished products segment, followed by Bulk medicine. The majority of the company's sales are generated in China, followed by Europe, India and other countries.
67GF Score
Get the complete analysis for FRA:UNJ
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:UNJ has been successfully added to your 
